HOME >> BIOLOGY >> NEWS
FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections

Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) for a new use the treatment of complicated intra-abdominal infections (cIAI) in adults. AVELOX is the only marketed fluoroquinolone antibiotic approved by the FDA as monotherapy to treat this indication. The FDA approval to treat cIAI is the sixth indication for AVELOX.

AVELOX, available in tablet and intravenous (I.V.) formulations, was developed by Bayer Pharmaceuticals Corporation and is marketed in the United States by Schering-Plough.

Intra-abdominal infections are caused by disease, trauma or surgery in the abdomen that cause bacteria to leak from the gastrointestinal tract into adjacent tissue there are approximately 3.5 million cases in the United States each year, with many patients contracting the infection secondary to appendicitis. [1]

"The FDA approval of AVELOX to treat complicated intra-abdominal infections is welcome news, providing doctors with an effective treatment option for their patients, and giving patients convenient once-daily dosing and an easy transition from I.V. to oral therapy when they leave the hospital," said Joseph S. Solomkin, M.D., professor in the department of surgery and director of research of the division of trauma/critical care at the University of Cincinnati College of Medicine.

With this FDA approval, AVELOX is indicated for the treatment of adults with cIAI, including polymicrobial infections such as abscesses caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron or Peptostreptococcus species.

The FDA approval was based on results from clinical studies in cIAI patients showing that sequential I.V. or oral monotherapy with AVELOX once daily was
'"/>


30-Nov-2005


Page: 1 2

Related biology news :

1. FDA approves new epilepsy indication for Lamictal
2. US govt approves multi-million $ wild bird avian flu surveillance network
3. FDA approves extended dosing of Aranesp
4. FDA approves first medical device using Rutgers biomaterial
5. DFG approves additional six research training groups
6. FDA approves ABRAXANE(TM) for metastatic breast cancer
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New system of wastewater treatment could reduce the size of treatment plants by half
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
11. System to analyze beating heart stem cells could lead to heart attack treatments

Post Your Comments:
(Date:11/6/2014)... occur because of metastasis, yet progress in preventing ... , "It,s been particularly challenging to design drugs ... fellow in systems biology at Harvard Medical School. ... after they,ve already metastasized." , Gujral and colleagues ... help researchers better understand how metastasis begins. Their ...
(Date:11/5/2014)... associate professor of biology in the UTSA College ... the nation selected to receive a two-year $300,00 ... Exploratory Research (EAGER). The funding supports President Obama,s ... to create new technology that will demystify complex ... behaviors in neuroscience are broken into the interactions ...
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2
(Date:11/18/2014)... Atlanta, Georgia (PRWEB) November 18, 2014 ... Automotive (Melbourne, Australia) recently formed a partnership with ... University, Swinburne University of Technology, and the USDA’s ... structural components reinforced with nanocellulose. Nanocellulose is a ... The goal of the project is to replace ...
(Date:11/18/2014)... PDL BioPharma, Inc. (PDL) (NASDAQ: ... acquisition of Durata Therapeutics, Inc. by Actavis, PDL has ... of PDL,s credit agreement with Durata, which included repayment ... accrued interest, and prepayment and change of control premiums. ... transaction with Durata in which PDL agreed to provide ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper " Traceability ... becoming the first calibration laboratory in the world ... the microgram range. National Metrology Institutes (NMI's), private ... in nanotechnology applications will benefit from understanding the ... weights in the range of 0.05 mg to ...
(Date:11/15/2014)... 13, 2014 Collaborative Consulting, a privately ... named one of the Boston Globe’s “Top Places to ... Businesses in Massachusetts to receive the honor. , The ... take care of their most valuable resource: the people ... annually, and are based on an array of criteria, ...
Breaking Biology Technology:American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2
Cached News: